Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survivalHervé Avet-Loiseau, Michel Attal, Loic Campion, et al.The New England Journal of Medicine|May 11, 2012
Lenalidomide maintenance after stem-cell transplantation for multiple myelomaMichel Attal, Valerie Lauwers-Cances, Gerald Marit, et al.Blood|February 1, 2015
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experienceBenjamin Hebraud, Florence Magrangeas, Alice Cleynen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related deathPhilippe Moreau, Michele Cavo, Pieter Sonneveld, et al.Blood|January 16, 2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02Xavier Leleu, Michel Attal, Bertrand Arnulf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2017
Prospective Evaluation of Magnetic Resonance Imaging and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM StudyPhilippe Moreau, Michel Attal, Denis Caillot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experienceHervé Avet-Loiseau, Cyrille Hulin, Loic Campion, et al.Blood|August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaPhilippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.Haematologica|April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patientsMarie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.Blood|October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.Pageof 4